The lung disease bronchiectasis plays out as a vicious cycle. Infection leads to inflammation followed by the impaired ability to clear the excess mucus coughed up from the lungs. These problems lead ...
The lung disease affects up to 500,000 U.S. adults The daily pill could generate $5 billion in annual sales WEDNESDAY, Aug. 13, 2025 (HealthDay News) — For the first time, people with bronchiectasis ...
The FDA approved oral brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis in adults and kids 12 years and up, drugmaker Insmed announced on Tuesday. A first-in-class ...
Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...
For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...
The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at the European Respiratory Society Congress, held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback